A systematic review of 13 studies found that the cost-effectiveness of interventions for inherited cardiomyopathies varies by patient population, with cascade genetic testing being highly cost-effective.
Systematic Review (n=13)
Are diagnostic and treatment interventions cost-effective in patients with inherited cardiomyopathies (HCM and DCM)?
Knowledge of the societal and economic burden of inherited cardiomyopathies is limited, but current evidence suggests genetic testing and ICDs are generally cost-effective while highlighting the need for broader cost inclusion in future research.
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are commonly inherited heart conditions associated with a high risk of heart failure and sudden cardiac death. To understand the economic and societal disease burden, this study systematically identified and reviewed cost-of-illness (COI) studies and economic evaluations (EEs) of various interventions for HCM and DCM. A literature search was performed in MEDLINE, EMBASE, NHS EED, EconLit and Web of Science to identify COI studies and EEs published between 1 January 2010 and 28 April 2021. The selection of studies and their critical appraisal were performed jointly by two independent researchers. For the quality assessment, the 'Consensus on Health Economic Criteria' list was used. Two COI studies and 11 EEs were eligible for inclusion. Cost-effectiveness varied among interventions and depended on the targeted patient population. Both COI studies identified only hospitalisation costs in HCM. The mean study quality was high in EEs but low in COI studies. Most studies excluded costs for patients, caregivers and productivity losses. Overall, knowledge of the societal and economic burden of inherited cardiomyopathies is limited. Future research needs to include quality-adjusted life years and a broader range of costs to provide an information base for optimising care for affected patients.
Wiethoff et al. (Fri,) conducted a systematic review in Inherited cardiomyopathies (Hypertrophic cardiomyopathy and dilated cardiomyopathy) (n=13). Various diagnostic and treatment interventions (e.g., cascade genetic testing, ICDs, VADs, WCDs, AEDs) vs. Various comparators (e.g., clinical surveillance, no device, watchful waiting) was evaluated on Cost-effectiveness (Incremental cost-effectiveness ratio) and cost-of-illness. A systematic review of 13 studies found that the cost-effectiveness of interventions for inherited cardiomyopathies varies by patient population, with cascade genetic testing being highly cost-effective.